These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31871303)

  • 1. Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations.
    Stuebler AG; Jansen M
    Mol Pharmacol; 2020 Mar; 97(3):171-179. PubMed ID: 31871303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors.
    Pandhare A; Pappu AS; Wilms H; Blanton MP; Jansen M
    Neuropharmacology; 2017 Feb; 113(Pt A):89-99. PubMed ID: 27671323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer drug irinotecan inhibits homomeric 5-HT3A and heteromeric 5-HT3AB receptor responses.
    Nakamura Y; Ishida Y; Yamada T; Shimada S
    Biochem Biophys Res Commun; 2011 Nov; 415(2):416-20. PubMed ID: 22044840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single channel mutation alters agonist efficacy at 5-HT3A and 5-HT3AB receptors.
    Thompson AJ; Lummis SC
    Br J Pharmacol; 2013 Sep; 170(2):391-402. PubMed ID: 23822584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General anesthetic-induced channel gating enhancement of 5-hydroxytryptamine type 3 receptors depends on receptor subunit composition.
    Solt K; Stevens RJ; Davies PA; Raines DE
    J Pharmacol Exp Ther; 2005 Nov; 315(2):771-6. PubMed ID: 16081679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subunit-dependent modulation of the 5-hydroxytryptamine type 3 receptor open-close equilibrium by n-alcohols.
    Rüsch D; Musset B; Wulf H; Schuster A; Raines DE
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1069-74. PubMed ID: 17360702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of human 5-hydroxytryptamine type 3AB receptors by volatile anesthetics and n-alcohols.
    Stevens R; Rüsch D; Solt K; Raines DE; Davies PA
    J Pharmacol Exp Ther; 2005 Jul; 314(1):338-45. PubMed ID: 15831437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan.
    Nakamura Y; Ishida Y; Yamada T; Kondo M; Shimada S
    J Neurochem; 2013 Apr; 125(1):7-15. PubMed ID: 23305320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SR 57227A is a partial agonist/partial antagonist of 5-HT
    Nakamura Y; Kondo M; Koyama Y; Shimada S
    Biochem Biophys Res Commun; 2019 Jan; 508(2):590-596. PubMed ID: 30509492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of recognition loops B and D in the activation of human 5-HT₃ receptors by 5-HT and meta-chlorophenylbiguanide.
    Michaelson SD; Paulsen IM; Kozuska JL; Martin IL; Dunn SM
    Neuropharmacology; 2013 Oct; 73():398-403. PubMed ID: 23810831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a binding site for bupropion in
    Pirayesh E; Do HQ; Ferreira G; Pandhare A; Gallardo ZR; Jansen M
    bioRxiv; 2023 Oct; ():. PubMed ID: 37873398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct interaction of the resistance to inhibitors of cholinesterase type 3 protein with the serotonin receptor type 3A intracellular domain.
    Nishtala SN; Mnatsakanyan N; Pandhare A; Leung C; Jansen M
    J Neurochem; 2016 May; 137(4):528-38. PubMed ID: 26875553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yokukansan contains compounds that antagonize the 5-HT
    Nakamura Y; Ishida Y; Kondo M; Shimada S
    Phytomedicine; 2018 Apr; 43():120-125. PubMed ID: 29747744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pyrrole etomidate analog carboetomidate potently inhibits human 5-HT3A receptor function: comparisons with etomidate and potential implications for emetogenesis.
    Desai R; Miller KW; Raines DE
    Anesth Analg; 2013 Mar; 116(3):573-9. PubMed ID: 23400978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct subunit-dependent multimodal 5-hydroxytryptamine3 receptor antagonism by methadone.
    Deeb TZ; Sharp D; Hales TG
    Mol Pharmacol; 2009 Apr; 75(4):908-17. PubMed ID: 19131665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modular design of Cys-loop ligand-gated ion channels: functional 5-HT3 and GABA rho1 receptors lacking the large cytoplasmic M3M4 loop.
    Jansen M; Bali M; Akabas MH
    J Gen Physiol; 2008 Feb; 131(2):137-46. PubMed ID: 18227272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues.
    Kim EJ; Felsovalyi K; Young LM; Shmelkov SV; Grunebaum MF; Cardozo T
    Psychopharmacology (Berl); 2018 Sep; 235(9):2643-2650. PubMed ID: 29961917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menthol inhibits 5-HT3 receptor-mediated currents.
    Ashoor A; Nordman JC; Veltri D; Yang KH; Shuba Y; Al Kury L; Sadek B; Howarth FC; Shehu A; Kabbani N; Oz M
    J Pharmacol Exp Ther; 2013 Nov; 347(2):398-409. PubMed ID: 23965380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors.
    Damaj MI; Carroll FI; Eaton JB; Navarro HA; Blough BE; Mirza S; Lukas RJ; Martin BR
    Mol Pharmacol; 2004 Sep; 66(3):675-82. PubMed ID: 15322260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ginsenoside Rg2 on the 5-HT3A receptor-mediated ion current in Xenopus oocytes.
    Choi S; Lee JH; Oh S; Rhim H; Lee SM; Nah SY
    Mol Cells; 2003 Feb; 15(1):108-13. PubMed ID: 12661769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.